Bookbuilding IPO | ₹[.] Cr | Listing at BSE, NSE |
SEBI has approved the Initial Public Offer (IPO) of Allchem Lifescience Ltd. on August 21, 2025. The company will proceed with next steps to launch the Initial Public Offer (IPO) subject to market conditions and other approvals. The SEBI approval is valid for 12 months.
Allchem Lifescience Ltd. IPO is a Book Build Issue consisting of fresh issue of ₹190.00 crores and an offer for sale (OFS) of upto 0.72 crore equity shares.
The equity shares are proposed to be listed on NSE and BSE. Emkay Global Financial Services Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Allchem Lifescience IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Fresh Issue | [.] shares (agg. up to ₹190 Cr) |
| Offer for Sale | 71,55,000 shares of ₹10 (agg. up to ₹[.] Cr) |
| Share Holding Pre Issue | 7,65,40,230 shares |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Tue, Mar 18, 2025 |
| SEBI/Exchange approval received | Thu, Aug 21, 2025 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Offer |
| Retail Shares Offered | Not less than 35% of the Offer |
| NII Shares Offered | Not less than 15% of the Offer |
Incorporated in 2017, Allchem Lifescience Limited is manufacturer of active pharmaceutical ingredient (API) intermediates and specialty chemicals. The company focuses on producing key starting materials (KSMs), generic API intermediates, and speciality chemicals to cater to both domestic and international pharmaceutical and chemical industries.
Business Verticals
Allchem Lifescience Limited operates through two primary business segments:
Product Portfolio & Capabilities
Allchem Lifescience Limited has developed the capability to manufacture 263 products, demonstrating expertise in various organic chemical compounds and advanced chemistries.
Clientele
The company serves a diverse range of domestic and international customers, including:
Manufacturing & Infrastructure
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 246.30 | 224.65 | 186.68 | 124.02 |
| Total Income | 78.53 | 138.07 | 106.03 | 109.42 |
| Profit After Tax | 10.89 | 23.41 | 17.99 | 14.14 |
| NET Worth | 90.74 | 79.89 | 56.49 | 38.58 |
| Reserves and Surplus | 86.49 | 75.64 | 52.24 | 35.08 |
| Total Borrowing | 106.90 | 104.97 | 97.17 | 49.53 |
| Amount in ₹ Crore | ||||
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹76.16 (+6.60%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹586.15 (-0.50%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,054.10 (+0.55%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,438.20 (+0.49%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹175.59 (-2.00%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.39 (-1.09%) |
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹139.50 (+7.31%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹40.39 (-1.75%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹183.50 (-0.27%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹259.15 (-0.06%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹257.80 (-0.46%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹100.95 (+0.25%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹235.20 (+5.00%) |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment or pre-payment, in full or in part, of certain of the outstanding borrowings availed by the Company. | 130.00 |
| 2 | General Corporate Purposes | |
| Total | 130.00 |
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 34.33% |
| ROCE | 22.87% |
| Debt/Equity | 1.31 |
| RoNW | 34.33% |
| PAT Margin | 17.03% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 3.06 | |
| Promoter Holding | 100% |
Lead Manager Reports
Allchem Lifescience IPO is a main-board IPO of 0 equity shares of the face value of ₹10 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .
The Allchem Lifescience IPO open and close dates are not available as of now.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Allchem Lifescience IPO using UPI as a payment gateway. Zerodha customers can apply in Allchem Lifescience IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Allchem Lifescience IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Allchem Lifescience IPO dates are not announced. Please check back again after some time.
Allchem Lifescience IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Allchem Lifescience IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Allchem Lifescience IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Allchem Lifescience IPO allotment status.
The Allchem Lifescience IPO listing date is not yet announced. The tentative date of listing is .
